UGT1A1 and UGT1A9 Are Responsible for Phase II Metabolism of Tectorigenin and Irigenin In Vitro

被引:9
|
作者
Li, Ji [1 ]
Xu, Zhangyao [2 ]
Gu, Jifeng [2 ,3 ]
机构
[1] Fudan Univ, Eye & ENT Hosp, Dept Radiat Oncol, Shanghai 200031, Peoples R China
[2] Fudan Univ, Eye & ENT Hosp, Dept Pharm, Shanghai 200031, Peoples R China
[3] Fudan Univ, Sch Basic Med Sci, Shanghai Key Lab Bioact Small Mol, Shanghai 200031, Peoples R China
来源
MOLECULES | 2022年 / 27卷 / 13期
关键词
tectorigenin; irigenin; glucuronidation; human liver microsomes; response factor method; HUMAN UDP-GLUCURONOSYLTRANSFERASES; BELAMCANDA-CHINENSIS; DIFFERENT DOSAGES; RAT URINE; GLUCURONIDATION; IDENTIFICATION; JATRORRHIZINE; EXCRETION; ENZYMES; 1A9;
D O I
10.3390/molecules27134104
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tectorigenin and irigenin are biologically active isoflavones of Belamcanda chinensis (L.) DC. Previous studies indicated that both compounds could be metabolized in vivo; however, the kinetic parameters of enzymes involved in the metabolization of tectorigenin and irigenin have not been identified. The aim of this study was to investigate UGTs involved in the glucuronidation of tectorigenin and irigenin and determine enzyme kinetic parameters using pooled human liver microsomes (HLMs) and recombinant UGTs. Glucuronides of tectorigenin and irigenin were identified using high-performance liquid chromatography (HPLC) coupled with mass spectrometry and quantified by HPLC using a response factor method. The results showed that tectorigenin and irigenin were modified by glucuronidation in HLMs. One metabolite of tectorigenin (M) and two metabolites of irigenin (M1 and M2) were detected. Chemical inhibition and recombinant enzyme experiments revealed that several enzymes could catalyze tectorigenin and irigenin glucuronidation. Among them, UGT1A1 and UGT1A9 were the primary enzymes for both tectorigenin and irigenin; however, the former mostly produced irigenin glucuronide M1, while the latter mostly produced irigenin glucuronide M2. These findings suggest that UGT1A1 and UGT1A9 were the primary isoforms metabolizing tectorigenin and irigenin in HLMs, which could be involved in drug-drug interactions and, therefore, should be monitored in clinical practice.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
    Hiromichi Maeda
    Shoichi Hazama
    Abdiev Shavkat
    Ken Okamoto
    Koji Oba
    Junichi Sakamoto
    Kenichi Takahashi
    Masaki Oka
    Daisuke Nakamura
    Ryouichi Tsunedomi
    Naoko Okayama
    Hideyuki Mishima
    Michiya Kobayashi
    Molecular Diagnosis & Therapy, 2014, 18 : 333 - 342
  • [2] Differences in UGT1A1, UGT1A7, and UGT1A9 Polymorphisms between Uzbek and Japanese Populations
    Maeda, Hiromichi
    Hazama, Shoichi
    Shavkat, Abdiev
    Okamoto, Ken
    Oba, Koji
    Sakamoto, Junichi
    Takahashi, Kenichi
    Oka, Masaki
    Nakamura, Daisuke
    Tsunedomi, Ryouichi
    Okayama, Naoko
    Mishima, Hideyuki
    Kobayashi, Michiya
    MOLECULAR DIAGNOSIS & THERAPY, 2014, 18 (03) : 333 - 342
  • [3] UGT1A1 and UGT1A9 variants affect thyroxine glucuronidation in human livers.
    Graber, AY
    Innocenti, F
    Ramirez, J
    Chen, PX
    Das, S
    Ratain, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P73 - P73
  • [4] Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38.
    Singh, A
    Paoluzzi, L
    Price, D
    Danesi, R
    Mathijssen, RH
    Verweij, J
    Figg, WD
    Sparreboom, A
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 145S - 145S
  • [5] Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
    Peer, Cody J.
    Sissung, Tristan M.
    Kim, AeRang
    Jain, Lokesh
    Woo, Sukyung
    Gardner, Erin R.
    Kirkland, C. Tyler
    Troutman, Sarah M.
    English, Bevin C.
    Richardson, Emily D.
    Federspiel, Joel
    Venzon, David
    Dahut, William
    Kohn, Elise
    Kummar, Shivaani
    Yarchoan, Robert
    Giaccone, Giuseppe
    Widemann, Brigitte
    Figg, William D.
    CLINICAL CANCER RESEARCH, 2012, 18 (07) : 2099 - 2107
  • [6] Raloxifene glucuronidation in liver and intestinal microsomes of humans and monkeys: contribution of UGT1A1, UGT1A8 and UGT1A9
    Kishi, Naoki
    Takasuka, Akane
    Kokawa, Yuki
    Isobe, Takashi
    Taguchi, Maho
    Shigeyama, Masato
    Murata, Mikio
    Suno, Manabu
    Hanioka, Nobumitsu
    XENOBIOTICA, 2016, 46 (04) : 289 - 295
  • [7] Influence of genetic variants in UGT1A1 and UGT1A9 on the in vivo glucuronidation of SN-38
    Paoluzzi, L
    Singh, AS
    Price, DK
    Danesi, R
    Mathijssen, RHJ
    Verweij, J
    Figg, WD
    Sparreboom, A
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (08): : 854 - 860
  • [8] Role of HNF-1A in the regulation of UGT1A1, UGT1A9 and UGT2B7 MRNA expression.
    Mirkov, S
    Innocenti, F
    Liu, W
    Chen, PX
    Ramirez, J
    Undevia, SD
    Das, S
    Ratain, MJ
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P61 - P61
  • [9] HEPATOCYTE NUCLEAR FACTOR 1 ALPHA AND 4 ALPHA ARE CAUSAL FACTORS RESPONSIBLE FOR INTERINDIVIDUAL VARIABILITIES OF UGT1A6 AND UGT1A9 MRNA BUT NOT UGT1A1, UGT1A3 AND UGT1A4 MRNA IN HUMAN LIVERS
    Aueviriyavit, Sasitorn
    Furihata, Tomomi
    Morimoto, Kaori
    Kobayashi, Kaoru
    Chiba, Kan
    DRUG METABOLISM REVIEWS, 2007, 39 : 298 - 298
  • [10] Structure-metabolism relationships for the glucuronidation of flavonoids by UGT1A3 and UGT1A9
    Xie, Shenggu
    Chen, Yakun
    Chen, Shuqing
    Zeng, Su
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2011, 63 (02) : 297 - 304